1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079


Delayed Nasdaq  -  04:00 2022-08-12 pm EDT
171.18 USD   -0.37%
08/11INSIDER SELL : Moderna
08/11Moderna, Inc. CEO Stéphane Bancel, Goldman Sachs Chairman and CEO David Solomon, U.S. Senator John Hickenlooper, Among 2022 Mentors for Jeff Ubben Posse Fellows Program
08/11Moderna says vaccine facility in Montreal suburb could be operational by end of 2024
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

US FDA wants COVID boosters targeting Omicron BA.4, BA.5 subvariants

06/30/2022 | 05:34pm EDT

June 30 (Reuters) - The U.S. Food and Drug Administration on Thursday recommended COVID-19 vaccine manufacturers change the design of their booster shots beginning this fall to include components tailored to combat the currently dominant Omicron BA.4 and BA.5 subvariants of the coronavirus.

If authorized, the changes would mark the first major retooling of COVID vaccines, but also could slow their rollout as the FDA has recommended a design somewhat different from what the companies had already tested and started producing.

The FDA will not require new studies testing the BA.4/BA.5 shots in humans to be completed for authorization, a top agency official told Reuters, similar to how annual changes to flu vaccines are handled.

"In a sense, we are chasing the virus, just as we do with influenza, and how close we can get to the variants that are prominent at the time, we'll have to wait and see," said Dr. William Schaffner, an infectious disease expert at Vanderbilt University Medical Center, adding that redesigned vaccines could provide better protection than current ones.

The FDA said companies would not need to change the vaccine for the primary vaccination series, saying the coming year will be "a transitional period when this modified booster vaccine may be introduced."

The new booster shots would be bivalent vaccines, targeting both the original virus as well as the Omicron subvariants.

The decision follows a recommendation by the agency's outside advisers to change the vaccine design this fall to combat more prevalent versions of the coronavirus.

BA.4 and BA.5 are estimated to account for more than 50% of U.S. infections, according the U.S. Centers for Disease Control and Prevention, and have also become dominant elsewhere.

The FDA said on Thursday that it hoped the modified vaccines could be used in early to mid-fall.

Scientists have suggested redesigned boosters could spur a broader range of immune responses that might also protect against future variants that may emerge.

"Predicting the future with COVID-19 in particular is hazardous, because COVID has faked us out on a number of occasions," Schaffner said.


Regulators from other countries are seriously considering using new boosters based on the BA.1 Omicron variant that caused the massive surge in cases last winter, top FDA official Dr. Peter Marks said in an interview.

"Some may want a vaccine more rapidly. That (vaccine) is going to be available more rapidly," Marks said, after a meeting of international regulators on Thursday.

Advisers to the World Health Organization preferred BA.1-based boosters, arguing that the variant is more distinct and could generate a broader response than the more recently circulating subvariants.

Pfizer Inc with partner BioNTech SE and Moderna Inc have been testing versions of their vaccines modified to combat the BA.1 Omicron variant.

Although they have said those vaccines generated a good immune response against BA.1 and the more recently circulating variants, they did see a lower response against BA.4 and BA.5.

The companies had already been manufacturing their BA.1 vaccines, and said on Tuesday switching to a BA.4/BA.5 design could delay their introduction.

Pfizer/BioNTech, which on Wednesday announced a $3.2 billion contract to supply more COVID vaccine doses to the United States, said they would have a substantial amount of BA.4/BA.5 vaccine ready for distribution by the first week of October.

Moderna said it would be late October or early November before its modified vaccine is ready.

The FDA has directed manufacturers to launch clinical trials to study the BA.4/5 vaccines, but said they would evaluate data on their previous BA.1-based vaccines to support authorization of the retooled shots.

Marks said data from the new trial will be important to gauge the continued effectiveness of the boosters against new variants that may arise.

(Reporting by Michael Erman in New Jersey and Manas Mishra in Bengaluru, Additional Reporting by Leroy Leo in Bengaluru; Editing by Jonathan Oatis and Bill Berkrot)

© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE 1.11% 160.35 Delayed Quote.-37.80%
MODERNA, INC. -0.37% 171.18 Delayed Quote.-32.60%
PFIZER, INC. 3.77% 50.11 Delayed Quote.-15.14%
SCHAFFNER HOLDING AG -0.63% 313 Delayed Quote.3.96%
All news about MODERNA, INC.
08/11INSIDER SELL : Moderna
08/11Moderna, Inc. CEO Stéphane Bancel, Goldman Sachs Chairman and CEO David Solomon, U.S. S..
08/11Moderna says vaccine facility in Montreal suburb could be operational by end of 2024
08/10EUROPA-COVID-19 VACCINES : Commission and Moderna adapt delivery schedules for late summer..
08/09Novavax tumbles 30% as waning COVID-19 vaccine demand hits outlook
08/09European Commission, Moderna Map Out COVID-19 Vaccine Rollout for Autumn, Summer
08/09Novavax tumbles 31% as waning COVID vaccine demand hits revenue forecast
08/09MODERNA : And the European Commission (EC) Amend Covid-19 Vaccine Agreement to Supply Omic..
08/09Moderna And the European Commission (EC) Amend Covid-19 Vaccine Agreement to Supply Omi..
08/09Moderna, Inc. and European Commission Amend Covid-19 Vaccine Agreement to Supply Omicro..
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2022 21 892 M - -
Net income 2022 11 063 M - -
Net cash 2022 16 818 M - -
P/E ratio 2022 6,48x
Yield 2022 -
Capitalization 66 966 M 66 966 M -
EV / Sales 2022 2,29x
EV / Sales 2023 4,58x
Nbr of Employees 2 700
Free-Float 90,4%
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 19
Last Close Price 171,18 $
Average target price 214,00 $
Spread / Average Target 25,0%
EPS Revisions
Managers and Directors
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-32.60%66 966
LONZA GROUP AG-23.32%46 073
IQVIA HOLDINGS INC.-12.88%45 135
SEAGEN INC.10.05%32 099
CELLTRION, INC.5.05%22 493